3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Phase 1
1
Status
Completed
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
2
CNS
2
Conditions
Carcinoma, Non-Small-Cell Lung
3
Meningeal Carcinomatosis
2
Lung Neoplasms
2
Brain Neoplasms
2
Respiratory Tract Diseases
1
Neoplasms
1
Interventions
Temozolomide
29
Bevacizumab
14
Radiotherapy
12
Trastuzumab
10
Lomustine
9
Capecitabine
8
paclitaxel-Angiopep-2 conjugate
6
Nivolumab
6
pembrolizumab
5
dabrafenib
5
abemaciclib
5
Radiation
5
icotinib
4
Surgical Procedures, Operative
4
Paclitaxel
4
Lapatinib
4
Irinotecan
4
Flucytosine
4
Dianhydrogalactitol
4
Corticotropin-Releasing Hormone
4
Chlorotoxin
4
Carboplatin
4
vocimagene amiretrorepvec
3
verubulin
3
tucatinib
3
osimertinib
3
motexafin gadolinium
3
XL647
3
Spermine Synthase
3
Radiosurgery
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
INDUSTRY
×
Brain Neoplasms
×
AZD3759
×
Clear all
NCT03653546
2025-09-10
BM
Alpha Biopharma (Jiangsu) Co., Ltd.
Phase 2/3
Completed
492 enrolled
NCT02228369
2021-01-05
BLOOM
AstraZeneca
Phase 1
Completed
108 enrolled